The importance of strict glycaemic control in reducing diabetes-related outcomes is well recognised. Yet, despite the range of available treatment options, clinical experience suggests that individuals with diabetes frequently fail to achieve good glucose control. Instead, patients often have poorly controlled, unpredictable blood glucose levels. In insulin-treated patients, one of the reasons for this may be the inherently variable action of exogenously injected insulin. For example, the currently available longer-lasting insulin preparations that aim to provide a continuous basal level of circulating insulin are associated with markedly variable action both between and within subjects. Unpredictable insulin action contributes to variable blood glucose control, which in addition to increasing the risk of hypoglycaemia has also been shown to be an independent risk factor for mortality. It is hoped that advances in longer-lasting insulin preparations will provide significant benefits to patients, improving control and reducing variability. A new, long-lasting analogue, insulin detemir, has been shown to be significantly less variable than other basal insulin preparations in pharmacological and clinical studies. The improved predictability in insulin response offered by insulin detemir may be associated with a number of clinical benefits including a reduction in hypoglycaemia and weight gain.
Introduction
Achieving consistent blood glucose control in individuals with diabetes is often an elusive goal. Patients typically have fluctuating glucose levels and frequent episodes of hypoglycaemia that limit glycaemic targets. Many factors are likely to influence blood glucose control including patient selfmanagement skills, diet, exercise and healthcare provision. 1 However, even if patients have excellent self-management skills and all the necessary care-giver support, glycaemic goals will be restricted by the limitations of currently available pharmacotherapies.
For many years, insulin preparations formulated from animal and human insulin were the only preparations available for the treatment of diabetes. These insulins have undoubtedly prolonged lives and limited the incidence and progression of diabetes-related complications, but their tendency to self-associate when in high concentration results in delayed and unpredictable absorption following subcutaneous injection. This limits their success in recreating the physiological norm of a low, continuous, basal level of circulating insulin supplemented by surges of insulin to counteract mealtime nutrient intake, thus compromising consistent blood glucose control in individuals with diabetes.
The development of insulin analogues with altered pharmacological properties more suitable for subcutaneous injection has, however, brought us to a certain extent closer to the ultimate goal of normal metabolic control in people with diabetes. This article will consider the potential impact of a new basal insulin analogue, insulin detemir, on the attainment of predictable glucose control.
What makes a good insulin analogue?
Two features can be used to assess the clinical potential of an insulin preparation. One is its mean blood glucose-lowering action and the other is the extent to which that profile is reproducible with each individual injection. In the case of basal insulin preparations, the aim is to deliver a continuous low level of insulin into the circulation throughout the day. One of the preparations most commonly used for this purpose is NPH insulin, a human insulin with a protracted action resulting from the addition of zinc and protamine. NPH insulin acts for 12-16 h; however, its mean pharmacodynamic profile indicates a peak in activity 4-8 h after injection. [2] [3] [4] [5] This type of peaked activity is not evident in normal basal insulin secretion and can compromise glycaemic control, increasing the risk of hypoglycaemia. To improve basal insulin substitution, it is therefore necessary to develop an insulin preparation with a relatively peakless mean pharmacodynamic profile. However, improving the mean profile alone will not guarantee improved control in the clinic; insulins also need to have a predictable action. Individual injections can result in a range of glucose-lowering profiles but still provide a peakless mean blood glucose-lowering profile (Figure 1) . So, while the insulin preparation looks good on paper, in the clinic its unpredictable action will produce a diverse range of responses both between and within patients, making the attainment of consistently well-controlled blood glucose unrealistic. Thus, protracted action is important but the extent of the variability in response must not be forgotten.
Variability: manifestations and assessment
Variability may manifest as between-subject (or interindividual) variability, in which the same injection dose in different patients will elicit a different blood glucose response, or within-subject (or intraindividual) variability, in which the same dose injected into the same patient at the same time on different days will cause a different blood glucose-lowering effect. Between-subject variability can be managed through a period of dose titration. Within-subject variability is more problematic, however, and will affect glycaemic control throughout treatment.
Variability can be assessed in a number of ways, but two of the most common measurements are standard deviation (s.d.) and coefficient of variation (CV). Both measures provide information on how tightly the individual scores or profiles are clustered around the mean, and in both cases, the bigger the value, the more variance there is. CV has an added advantage over s.d. as it is typically calculated by dividing the s.d. of the sample by the mean and multiplying the outcome by 100 to give a percentage. This therefore provides an arbitrary number that is not restricted to the units in which the study was conducted, which can facilitate comparisons between studies and insulin preparations.
Why does variability in insulin action matter?
Variability in the action of insulin results in variable, unpredictable blood glucose levels. This increases the risk of hypoglycaemia, limits glycaemic targets and is exceptionally frustrating for patients who experience erratic glucose control despite faithfully following treatment guidelines. This latter consequence may result in despondency and lack of motivation, which are likely to compromise attainment of glycaemic targets still further.
Blood glucose that varies from day to day has been associated with a number of negative outcomes. In a study of 98 patients with type I diabetes treated with multiple insulin injections or insulin pumps, within-subject variability in blood glucose (as assessed by the s.d. of selfmonitored glucose values at five time points every 2 days for 4 weeks) was positively correlated with mean glucose (r ¼ 0.48, P ¼ 0.0001) and hypoglycaemic events (r ¼ 0.31, P ¼ 0.002). 6 Thus, variable blood glucose increases the likelihood of hyperglycaemia and its related consequences. The observation that variability in blood glucose also correlates with hypoglycaemia is not surprising and has clinical implications, as hypoglycaemia, particularly at night, is a major limiting factor in the glycaemic targets that patients are willing to aim for. In addition, patients may consume additional food a few hours after meals to reduce the likelihood of hypoglycaemia. In addition to increasing the risk of hyperglycaemia, this action is likely to contribute to weight gain, which is frequently observed with insulin therapy. Blood glucose variability has also been shown to be an independent risk factor for mortality. In a study of 1409 patients with type II diabetes, fasting plasma glucose was measured at least twice a year for 3 y, before a 10-y follow-up period to assess mortality. 7 Patients were stratified into tertiles according to their mean fasting plasma glucose reading and their CV for fasting plasma glucose. Each individual parameter correlated positively with mortality, but when both factors were included in the analysis, only the CV for fasting plasma glucose was an independent predictor of death, indicating that the prognostic value of CV for fasting plasma glucose was greater than that of mean fasting plasma glucose.
Variability is pronounced with existing basal insulin preparations
While it has been known for many years that the action of insulin is variable, there has been limited interest in the assessment of variability or its clinical impact. 8, 9 The extent of variability in insulin action is affected by a number of Glycaemic control in reducing diabetes-related outcomes D Russell-Jones factors, but variability in absorption from the subcutaneous depot seems to be a major contributor; in one study, up to 80% of the variability in the action of NPH insulin could be accounted for by variability in absorption. 10, 11 Variability in absorption can be measured by observing the time taken for radioactivity to disappear from the injection site following an injection of labelled insulin, or by monitoring C-peptide, serum insulin or plasma insulin levels. Using the latter technique, Galloway et al 12 assessed the variability in absorption of several insulin preparations. Healthy volunteers (n ¼ 8) received a subcutaneous insulin injection of 0.2 U/kg on two separate occasions. Plasma insulin was measured at frequent intervals for up to 10 h. Following injections of NPH insulin, the within-subject CVs for maximum insulin concentration and time to reach maximum insulin concentration were 44 and 68%, respectively.
The equivalent values for Lente insulin were 28 and 34%. The variability in insulin action can be assessed by monitoring plasma glucose levels or the glucose infusion rate required to maintain a stable glycaemic state following an insulin injection (isoglycaemic clamp studies). In the above study, Galloway et al 12 used the former technique and reported that injections of NPH insulin were associated with marked variability in minimum plasma glucose concentration and time to reach minimum plasma glucose; the withinsubject CVs were 32 and 30%, respectively. The corresponding values for Lente insulin were 21 and 34%. A more recent study examined the variability in the effect of NPH insulin, Ultralente insulin and insulin glargine: healthy volunteers (n ¼ 36) received two, subcutaneous injections of each of the three insulins on separate occasions. 13 Insulin glargine is an insulin analogue that exhibits a fairly peakless, protracted mean profile relative to other basal insulin preparations. However, in this study, all three insulin preparations demonstrated marked withinsubject variability in action as assessed by euglycaemic clamps (Figure 2 ). Several factors contribute to the variability in insulin action, for example, site of injection, injection technique, orthostatic movement following injection and prevailing blood flow at the time of injection. However, some factors are inherent to the insulin preparation itself. For example, NPH insulin is a preformed precipitate and incomplete resuspension of this precipitate prior to injection can result in error in the injected dose. This source of variation is overcome when insulin is injected as a solution, such as is the case with insulin glargine. However, precipitation and redissolution following injection can add another source of variation, thus the inherent features of the insulin preparation will be important in ensuring consistent, predictable glycaemic control.
Action of insulin detemir is less variable than other basal preparations
Pharmacokinetic and pharmacodynamic studies Insulin detemir is a new, innovative basal insulin analogue recently approved by the European agency for the evaluation of medicinal products (EMEA). The pharmacological properties of insulin detemir suggest that it may allow more predictable control than other preparations. First, insulin detemir does not precipitate following injection, and second, it binds to albumin in the circulation and the subcutaneous depot, which may buffer against changes in absorption. 14, 15 Consistent with these characteristics, studies have shown that the pharmacokinetic properties of insulin detemir are less variable than other insulin preparations. [16] [17] [18] In one of these studies, healthy volunteers received a single 0.2 U/kg dose of insulin detemir or NPH insulin on each of 6 days.
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The within-subject variability of several pharmacokinetic parameters was significantly lower with insulin detemir than with NPH insulin (Table 1) . Consistent with these findings, pharmacodynamic studies have also shown that insulin detemir has a blood glucoselowering action that is more predictable than other basal insulin preparations. 3, 17 In a study of 54 patients with type I diabetes, each patient received a single subcutaneous dose (0.4 U/kg) of the same insulin preparation (insulin detemir, insulin glargine or NPH insulin) under euglycaemic clamp conditions on each of four study days. 17 Glucose infusion rates required to maintain a stable glycaemic state were subsequently measured for 24 h. The results showed that insulin detemir had a significantly less variable action than insulin glargine or NPH insulin (Figure 3 ). Glycaemic control in reducing diabetes-related outcomes D Russell-Jones
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Clinical data
Clinical studies have also shown that the action of insulin detemir is more predictable than that of NPH insulin. [19] [20] [21] [22] [23] [24] [25] This was well demonstrated in a study of patients with type I diabetes who injected insulin detemir (n ¼ 491) or NPH insulin (n ¼ 257) once daily at bedtime in addition to human insulin at mealtimes for 6 months. 24 All patients had previously followed a regimen of evening basal or premixed insulin injections supplemented by mealtime human insulin.
The study was open label as the physical characteristics of the insulins tested meant they could be clearly distinguished from each other. Fasting plasma glucose and HbA 1c were measured at baseline and following 3 and 6 months of treatment. Patients also recorded nine-point blood glucose profiles on three occasions, and self-monitored prebreakfast fasting blood glucose each day for 7 days in the last week of treatment. A subset of patients (insulin detemir, n ¼ 99; NPH insulin, n ¼ 39) underwent 24-h blood glucose monitoring using a continuous monitoring system. Fasting plasma glucose was significantly lower with insulin detemir than with NPH insulin at the end of treatment (10.3 vs 11.4 mmol/l, respectively, P ¼ 0.001). HbA 1c decreased with insulin detemir but did not differ significantly from NPH insulin treatment at the end of the trial (8.3 vs 8.41, respectively, P ¼ 0.083). During the last week of treatment, self-monitored fasting blood glucose was lower (7.27 vs 8.29 mmol/l, Po0.001) and more predictable (s.d.: 2.82 vs 3.6 mmol/l, Po 0.001) with insulin detemir than with NPH insulin.
Continuous blood glucose monitoring showed that insulin detemir resulted in a flatter glucose profile than NPH insulin, particularly at night (Figure 4a) . Furthermore, blood glucose was less variable with insulin detemir than with NPH insulin (Figure 4b ). The mean fluctuation over the 24-h period (calculated from each individual's 24-h mean blood glucose and indicated by the shaded area on Figure 4b ) was 55.11 mmol/l (derived from mmol/l/h) with insulin detemir compared with 62.99 mmol/l with NPH insulin (mean difference ¼ -9.67 mmol/l, P ¼ 0.039). Over the 7-h nocturnal period alone (23.00-06.00), the corresponding values were 14.71 and 17.09 mmol/l (mean difference ¼ -4.46 mmol/l, P ¼ 0.005).
Reduced variability in insulin action with insulin detemir has also been demonstrated in children and adolescents with type I diabetes. 23 A total of 347 patients received once-or twice-daily insulin detemir or NPH insulin in combination with mealtime insulin aspart for 26 weeks. At the end of the treatment period, mean fasting plasma glucose was significantly lower with insulin detemir than with NPH insulin (8.44 vs 9.58 mmol/l, respectively, P ¼ 0.022) and HbA 1c had decreased by 0.8% in both groups (mean difference insulin detemirÀNPH insulin ¼ 0.09%, NS). Furthermore, withinsubject variation in fasting plasma glucose was significantly reduced with insulin detemir (Table 2) . Consistent with the results of the above studies, reduced variability in glucose levels with insulin detemir relative to NPH insulin has been documented in five additional clinical trials (Table 2) . Glycaemic control in reducing diabetes-related outcomes D Russell-Jones
The improved predictability in insulin response demonstrated in trials with insulin detemir may be associated with a number of clinical benefits. For example, in the study by Heise et al, 17 described previously, the variabilities reported can be used to quantify, at a theoretical level, the risk of hyper-and hypoglycaemia with the three insulin preparations. For example, if a patient experiences a mean maximum glucose-lowering effect of 2 mg/(kg/min) following an insulin injection, the probability of a patient experiencing over twice this effect (and therefore being at risk of hypoglycaemia) was calculated to be 0.1% with insulin detemir, 3% with insulin glargine and 7% with NPH insulin. Likewise, if the average blood glucose-lowering effect of an insulin injection over 24 h is 1 mg/(kg/min), then the probability of experiencing less than half the mean 24-h insulin effect (and therefore being at risk of hyperglycaemia) was calculated as 0.5, 7 and 16% for the three preparations, respectively. Benefits have also been demonstrated in clinical studies. For example, Russell-Jones et al 24 reported that the risk of nocturnal hypoglycaemia with insulin detemir was 26% lower than with NPH insulin (P ¼ 0.003). Similarly, in the Robertson study of children and adolescents, the risk of nocturnal hypoglycaemia with insulin detemir was 36% lower than with NPH insulin (P ¼ 0.011). 26 Furthermore, insulin detemir is consistently associated with reduced weight gain relative to NPH insulin. 27 Thus, reducing variability may have marked clinical benefit.
Conclusion
The action of basal insulin preparations is often unpredictable. This unpredictability may contribute to poor, erratic glycaemic control and hypoglycaemia, and patients may become frustrated with their failure to attain glycaemic targets despite their consistent efforts. Furthermore, variable blood glucose has been associated with increased mortality. Insulin detemir is a new basal insulin analogue with a more predictable action than existing formulations. This improved predictability should facilitate attainment of glycaemic targets by limiting the risk of hypoglycaemia, particularly at night. Glycaemic control in reducing diabetes-related outcomes D Russell-Jones
